Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy is a phase 1/2, interventional study registered as NCT05764928 by Rgene Corporation, with a registry enrolment figure of 32 participants, started 2026-12-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: BLEX 404. Conditions listed: Nonsquamous Nonsmall Cell Neoplasm of Lung. Primary outcome: DLT determination; RDL Determination; Overall response rate (PR + CR) after 4 cycles of combination use. Lung eligibility wording from the registry: "Naïve patients with histologically or pathologically diagnosed with Advanced Inoperable or Metastatic non-small cell lung cancer and intended for first line treatment". Sites: Taiwan. No results are recorded here; the registry entry is the source.